Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer

Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an enzyme for testosterone auto-production. With standard dosing, evolution of resistance with treatment failure (radiographic progression) occurs at a median of ~16.5 months. We hypothesize time to progression (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingsong, Cunningham, Jessica J., Brown, Joel S., Gatenby, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703947/
https://www.ncbi.nlm.nih.gov/pubmed/29180633
http://dx.doi.org/10.1038/s41467-017-01968-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703947/
https://www.ncbi.nlm.nih.gov/pubmed/29180633
http://dx.doi.org/10.1038/s41467-017-01968-5

Ejemplares similares